Philips collaborates with leading institutes to bring its breakthrough spectral CT imaging into the interventional suite
Philips Angio CT
November 24, 2021
- Philips showcases world’s first spectral detector angio-CT solution at RSNA 2021
- Solution combines breakthrough spectral detector CT imaging and real-time fluoroscopy in a flexible environment where all modalities are operated through Philips Image-Guided Therapy System – Azurion with FlexArm
- Philips’ Spectral detector CT imaging in the interventional suite brings valuable additional information in minimally-invasive procedures for areas such as oncology, stroke, and trauma care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled its vision for interventional medicine by bringing its breakthrough spectral CT imaging technology into a hybrid Angio CT suite. By combining the company’s unique Spectral CT 7500 system and its Image-Guided Therapy System – Azurion with FlexArm in a single interventional suite solution, Philips aims to give interventionalists immediate table-side access to these two key imaging modalities so they can perform procedures requiring both CT and angio guidance in one room. For the development of this integrated solution Philips is closely collaborating with leading clinical institutes such as Mayo Clinic (Rochester, MN, U.S.) and Baptist Health’s Miami Cardiac & Vascular Institute (Miami, FL, U.S.). It is being presented at the 2021 Radiological Society of North America Annual Meeting (Chicago, USA, November 28 – December 2).
The goal of combining the breakthrough, first of a kind Spectral CT 7500 with the Azurion platform is to provide a seamless workflow environment in which all the necessary imaging modalities – are available directly at the patient table, fully controllable from the table-side work spot. When not in use, each modality glides smoothly away from the patient table into a parking position, giving the interventional team unrestricted access to the patient. Each system can work stand-alone if required. For interventionalists, it enables seamless efficient workflows without the need to move the patient from one imaging suite to another. For patients, this means their physicians can leverage the strengths of both systems during a single procedure.
Requiring just one scan to capture all the spectral information required to differentiate and quantify different tissues, Philips’ always-on spectral CT technology enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally-invasive procedures and more precise interventions. In oncology, spectral CT has also demonstrated a higher sensitivity in detecting malignant findings and has improved readings of incidental findings [1] [2].
“There has been a tremendous evolution in the image-guided therapy environment,” said Dr. Barry T. Katzen, founder and chief medical executive of Baptist’s Health’s Miami Cardiac & Vascular Institute. “We are really excited about the merger and integration of these technologies in that it might allow us to look at the treatment of a number of diseases in very new and innovative ways, potentially offering new treatment opportunities and improving patient care. I am looking forward to investigating the possibilities of this promising innovation.”
“With this innovation, we are taking a uniquely patient-centric approach, aimed at bringing the latest interventional imaging modalities to the patient table rather than moving the patient to the individual modalities,” said Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips. “We are excited to be co-creating the future of image guided therapy with leading clinical partners by combining the best of our award-winning modalities into a single suite.”
Follow @PhilipsLiveFrom for updates throughout RSNA 2021, and join Philips at RSNA 2021 where the company will spotlight its latest advanced technology driving connected workflows and smart connected imaging systems.
[1] Analysis by Aarhus University Hospital Aarhus, Denmark. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[2] Analysis by University Hospital Cleveland, USA. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel: +31 610 558 116
Email: joost.maltha@philips.com
Kathy O’Reilly
Philips Global Press Office
Tel. + 1 978-221-8919
E-mail kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
